| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.26B | +6.6% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | -3.7% |
| Gross margin | 48.7% | Net margin 19.4% |
| Revenue Q/Q | +0.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.13B | 51.3% |
| R&D | ¥0.03B | 11.5% |
| SG&A | ¥0.05B | 19.4% |
| Tax & other | ¥0.01B | 3.4% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
飞利信 ・ 朗玛信息 ・ 利德曼 ・ ST荣科 ・ 百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies